Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Other Accumulated Expenses (2020 - 2025)

Historic Other Accumulated Expenses for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $2.3 million.

  • Gain Therapeutics' Other Accumulated Expenses fell 604.32% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 604.32%. This contributed to the annual value of $2.4 million for FY2024, which is 1302.53% up from last year.
  • Per Gain Therapeutics' latest filing, its Other Accumulated Expenses stood at $2.3 million for Q3 2025, which was down 604.32% from $2.2 million recorded in Q2 2025.
  • Gain Therapeutics' Other Accumulated Expenses' 5-year high stood at $3.5 million during Q2 2024, with a 5-year trough of $848343.0 in Q2 2021.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $2.3 million (2025), whereas its average is $2.2 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first soared by 14530.54% in 2022, then tumbled by 3659.87% in 2025.
  • Over the past 5 years, Gain Therapeutics' Other Accumulated Expenses (Quarter) stood at $1.4 million in 2021, then soared by 50.2% to $2.1 million in 2022, then grew by 2.54% to $2.2 million in 2023, then increased by 13.03% to $2.4 million in 2024, then dropped by 4.14% to $2.3 million in 2025.
  • Its Other Accumulated Expenses stands at $2.3 million for Q3 2025, versus $2.2 million for Q2 2025 and $2.4 million for Q1 2025.